Biocompatibility analysis of PLA based candidate materials for cardiovascular stents in a rat subcutaneous implant model

Acta Histochem. 2020 Oct;122(7):151615. doi: 10.1016/j.acthis.2020.151615. Epub 2020 Sep 9.

Abstract

Modification of Polylactic acid (PLA), a biopolymer, is a strategy still to be fully explored for the next generation of bioresorbable vascular stent (BVS) biomaterials. With this focus, inclusions upto 5% of Polycaprolactone (PCL) and Magnesium in PLA were tested in the rat subcutaneous model and their cellular and tissue interactions characterized, specifically with respect to inflammatory response, angiogenesis and capsularization. The cytokines IL6, TNF Alpha and IL-1Beta were estimated in the peri-implant tissue, all of which showed a non-significant difference between the non-implanted animals and those containing PLA by 8 weeks, speaking to the benign nature of PLA as an implant biomaterial. Both modified materials, had increased macrophage counts and cytokine levels, except IL6 at 8 weeks. Vascularization only at 8 weeks in PLA PCL containing tissue was significantly higher than pure PLA, which may be more carefully controlled along with the material hydrophobicity for possible efforts towards therapeutic angiogenesis. Capsule thickness, measured by staining with both Hematoxylin & Eosin and Masson's Trichome did not show any differences between materials, including PLA.

Keywords: Bioresorbable vascular scaffolds (BVS); Endothelialization; Magnesium (Mg); Polycaprolactone (PCL); Polylactic acid (PLA); Rat subcutaneous testing.

MeSH terms

  • Animals
  • Biocompatible Materials* / adverse effects
  • Biocompatible Materials* / metabolism
  • Cardiovascular Abnormalities / surgery
  • Polyesters / adverse effects*
  • Polyesters / metabolism
  • Rats
  • Stents*
  • Tissue Scaffolds* / adverse effects

Substances

  • Biocompatible Materials
  • Polyesters
  • polycaprolactone
  • poly(lactide)